20

SSY Group LtdHKG 2005 Stock Report

Last reporting period 31 Dec, 2023

Updated 19 Sep, 2024

Last price

Market cap $B

1.48

Small

Exchange

XHKG - Hong Kong Exchange

2005.HK Stock Analysis

20

Neutral

Based on Eyestock quantitative analysis, 2005.HK`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

64/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

87.0 %

Greatly undervalued

Market cap $B

1.48

Dividend yield

6.73 %

Shares outstanding

2 972.68 B

SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company employs 4,800 full-time employees The company went IPO on 2005-12-20. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

View Section: Eyestock Rating